Document is current
Any future updates will be listed below
-
Authors
Horváth, Hanga Réka https://orcid.org/0000-0003-3055-420X
Andrási, Noémi https://orcid.org/0000-0001-6104-5446
Nagy, Eszter https://orcid.org/0009-0001-5698-5633
Imreh, Éva https://orcid.org/0000-0001-5343-9517
Farkas, Henriette https://orcid.org/0000-0003-2929-1721
-
Funding
Funding for this research was provided by:
Semmelweis University
- License Information
-
More Information
Article History
Received: 14 December 2025
Accepted: 26 February 2026
First Online: 14 March 2026
Declarations
:
: The study was approved by the Institutional Review Board of Semmelweis University, and informed consent was obtained from the participants in accordance with the Declaration of Helsinki (License number: 1067-5/2018/EÜIG).
: Not applicable.
: Hanga Réka Horváth received travel grants from Takeda and CSL Behring. Henriette Farkas has received research grants from CSL Behring, Takeda and Pharming and served as an advisor for these companies and Kalvista, Intellia, Ionis, Pharvaris, ONO Pharmaceuticals and Biocryst and has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, Kalvista, Pharvaris and Takeda. All other authors have no conflict of interest to declare.
